CZ13597A3 - Analgesic preparation exhibiting antiphlogistic and antiseptic activity - Google Patents

Abstract

Analgesic preparation exhibiting antiphlogistic and antiseptic action is made up of a mix of one or more benzo(c)phenanthridine alkaloids with rosemarinic acid in a physiologically safe vehicle. The alkaloid is bound in the preparation at a quantity of 0.001 to 2.0 % by weight, with rosemarinic acid at a quantity of 0.5-5 % by weight. The analgesic preparation is applied in the form of a gel, adhesive paste, mouthwash, spray and similar.

Description

The present invention relates to an analgesic preparation having an anti-inflammatory and antiseptic action, which is intended mainly for use in the oral cavity.

BACKGROUND OF THE INVENTION

For the treatment of inflammations in the oral cavity (eg periodontal trunks, pressure sores, mucosal ulcers or non-healing extraction wounds) a wide variety of preparations, most often containing compounds with antiseptic effects, are usually used in combination with astringent agents. The active ingredient of antiseptic preparations may be bisguanidines, bispyridines, salts of certain metals, oxidizing agents, phenols, pyrimidines, quaternary ammonium compounds, and some plant extracts, most of which are Matricaria chamomilla extract. More recent preparations often utilize the pronounced antimicrobial effect of Sanguinaria canadensis extract (Molinari, J.A., Molinari, G.E .: Is Mouthrinsing Before Dental Procedures Worthwhile ?, in JADA, 123, 75-80, (1992)). Corticosteroids, used to inhibit the inflammatory response mainly at the beginning of treatment, have anti-inflammatory activity without antiseptic effect. If analgesic efficacy is also desired, a suitable local anesthetic may be added.

In the context of the renaissance of natural medicines in human medicine, a number of natural substances and their derivatives have recently been tested for anti-inflammatory effects, such as bisabolol, ascin, terpenic alcohols and plant polyphenols. Quaternary benzo / c / phenenthridine alkaloids also have significant anti-inflammatory activity (Lenfeld, J., Kroutil, M., Marsalek, E., Slavik, J., Preininger, V., Simanek, V .: An Antiinflammatory Activity of Quartemary Benzophenanthridine Alkaloids from Chelidonium majus, in Planta Med., 43, 161-165 (1981)), which have been proposed to treat inflammatory mucosal and skin diseases. In addition, the analgesic effect of some quaternary benzo (c) phenenthridine alkaloids in intravenous administration has been described (Arzneim.-Forsch. 10, 135-137 (1960)).

-2Other substances with anti-inflammatory effects are rosmarinic acid, which is the main constituent of medicinal plant extracts such as flower beetles, lemon balm, sage, rosmarin, etc. In addition to its anti-inflammatory effects, it has antimicrobial and antioxidant properties; analgesic. Antimicrobial activity has been demonstrated against some non-pathogenic bacteria (Kuhnt, M., Pröbstle, A., Rimpler, H., Bauer, R., Heinrich, M .; Biological and Pharmacological Activities and Furtber Constituents of Hyptis verticillata, in Planta Med., 61, 227-232 (1995)), plant pathogenic bacteria and fungi (Ravn, H., Andary, C., Kovacs, G., Molgaard, P .: Caffeic Acid Esters and In vitro Inhibitor of Plant Pathogenic Bacteria and Fungi, in Biochem. Syst. Ecol., 17, 175-184 (1989)). The anti-inflammatory effect of rosmarinic acid has been demonstrated in vitro with human platelets (Gracza, L., Koch, H., Löfler, E .: Isolation of Rosmarinsáure aus Symphytum officinale and anti-inflammatory agents in in vitro model, in Arch. Pharm. (Weinheim), 318, 1090-1095 (1985)), in vivo experiments in rats (Zenk, M., Etschenberg, E., Graf. E .; Verwendung von Rosmarin bei dei Bekampfung von Entziindungen und hierbei eingesetzte Arzneimittel , in DE Patent 29 52 114 A1 (1981)) and in monkeys where application to the oral gingiva reduced inflammation and an anti-plaque effect was also noted (Van Dyke, TE, Braswell, L., Offenbacher, S. Inhibition of Gingivitis by Topical Application of Ebselen and Rosmarinic Acid, in Agents Action, 19, 376-377 (1986)).

A major disadvantage of the preparations mentioned in the introductory paragraph is that they do not combine high analgesic and anti-inflammatory activity with the desired retention in the mucosal epithelium and antiseptic activity against microorganisms in trunks and subgingival dental plaque. Long-term supplemental use of many antiseptics is often limited by their negative side effects (eg, chlorhexidine indigluconate causes increased tartar formation and loss of appetite), and anti-inflammatory corticoids also have undesirable hormonal activity.

3. Summary of the Invention

These drawbacks are overcome by an analgesic composition having an anti-inflammatory and antiseptic effect according to the invention. The composition of the present invention comprises at least one or a mixture of benzo / c / phenanthridine alkaloids selected from the group consisting of chelerythrin, sanguinarine, chelirubin, chelilutin, sanguirubin and sanguilutin in an amount of from 0.001 to 2% by weight. of the preparation and rosmarinic acid or a plant extract containing said acid in an amount of 0.5 to 5% by weight. in a physiologically acceptable vehicle. The alkaloid may be present in the formulation in the form of a pharmaceutically acceptable salt, eg, as a chloride or in the form of a base, rosmarinic acid may be free or in the form of a salt with a pharmaceutically acceptable metal, e.g., as a sodium salt.

The analgesic composition of the present invention, while significantly reducing the inflammatory-induced hyperalgesia, retains anti-inflammatory and antiseptic effects, wherein the addition of rosmarinic acid enhances the analgesic effect of the quaternary benzo (c) phenanthridine alkaloids alone. It is therefore suitable for the treatment of injuries and inflammations, especially the oral mucosa. In addition to having a broad spectrum of efficacy, it has also been found that the analgesic composition of the invention can be administered in a variety of dosage forms such as liquid gel, massage gel, adhesive paste, toothpaste, mouthwash, spray, and the like.

DETAILED DESCRIPTION OF THE INVENTION

Example 1

Dried Prunella vulgaris drug (289 g) was extracted in a Soxhlet apparatus with methanol (4000 mL, 20 h), the methanol was evaporated, the residue was dissolved in water (750 mL), acidified (H ₂ SO ₄ ) to pH 3-4 and the solution was extracted ten times with petroleum ether (200 mL). The aqueous phase was extracted ten times with ethyl acetate (150 mL), by evaporation

-4-ethyl acetate gave 9.66 g of a residue containing (HPLC) 60% rosmarinic acid. This extract was further referred to in Example 2.

Example 2

The residue of Prunella vulgaris extract (see Example 1, 9.0 g) was dissolved in toluene acetone 1: 1 (10 ml) and loaded onto a L 40/100 silica gel column (450 g). Toluene (200 mL) was used to elute, followed by toluene-acetone 35:65. Fractions containing (TLC) rosmarinic acid were combined and evaporated. The residue was dissolved in water (100 mL), rosmarinic acid crystallized upon inoculation and standing in the refrigerator for 24 h. After filtration, washing with cold water and drying (P2O5, 50 ° C), 3.23 g of product was obtained, m.p. Mp 167-170 ° C. This product was further used according to Example 3.

Example 3

The weighed 3 g of carboxymethylcellulose 300 is allowed to swell for 24 hours in 67 g of cold citrate buffer, pH 5, with occasional mixing. Transfer to an NTS bottle and sterilize at 105 ° C and exposure for 60 minutes. After cooling, the gel is cooled to about 5 ° C in a refrigerator. By rotating the bottle, the gel is mixed and allowed to warm to room temperature, 0.3 g of a mixture (3: 7) of commercially available sanguinarine and chelerythrin chlorides is added under strictly aseptic conditions, after dissolution 2 g of rosmarinic acid or 4 g of Prunella extract are added. vulgaris and finally the gel is supplemented with 30 g of ethanol. After complete dissolution and mixing, the gel is filled into sterile tubes in an aseptic environment.

The analgesic preparation thus prepared was tested for hyperalgesia induced by yeast and carrageenan inflammation in female Wistar rats. For comparison, a formulation containing 1% analgesic active diclofenac (Voltaren Emulgel) was used. The results are shown in the following table:

-5Table 1

Influence of inflammatory hyperalgesia due to yeast and carrageenan inflammation (x ± 95% confidence limit)

Preparation Inflammatory Hyperalgesia ³ Inflammatory Hyperalgesia ^b (mm Hg) (mm Hg)

control 170 ± 56 276 ± 77 san. + chel. 3: 7 182 ± 60 302 ± 89 0.3% nesig. nesig. rosmarin acid. 219 ± 38 284 ± 76 2% nesig. nesig. san. + chel. 3: 7 267 ± 93 384 ± 61 0.3% p <0.05 p <0.02 + rosmarin acid 2% Voltaren - 240 ± 95 351 ± ll · - Emulgel p <0.05 nesig.

“Yeast inflammation, carcinogenic inflammation, san. = sanguinarine, chel. = chelerythrin, rosmarin acid. = rosmarinic acid p <0.02 = difference between control and sample is statistically significant with probability p> 98% p <0.05 = difference between control and sample is statistically significant with probability p> 95% nesig. = difference between control and sample is insignificant.

Yeast inflammation of the rat paw was induced by the application of 0.1 ml of a 20% brewery yeast suspension. The gel was applied locally in an amount of 0.05 ml to the dorsum of the paw, 3 hours after induction of inflammation. Inflammatory pressure hyperalgesia (Randall-Seitt method) was measured 5 h (carrageenin inflammation) and 6 h (yeast inflammation) after application of test substances.

Table 1 shows that a mixture of sanguinarine, chelerythrin and rosmarinic acid (# 4) significantly (p <0.05 and 0.02, respectively) reduces inflammatory hyperalgesia compared to the same

-6the mixture of alkaloids without rosmainic acid (# 2) or compared to rosmarinic acid (# 3) to bring it to the level of diclofenac-based analgesic.

Claims (3)

PATENT CLAIMS An analgesic preparation having an anti-inflammatory and antiseptic effect, characterized in that it contains as active ingredient or a mixture of benzo (c) phenanthridine alkaloids selected from the group consisting of chelerythrin, sanguinarine, chelirubin, chelilutin, sanguirubin and sanguilutin in an amount of 0.001 to 2%. and rosmarinic acid or a plant extract comprising the acid in an amount of 0.5 to 5% by weight of the composition, in a physiologically acceptable vehicle. 2. An analgesic composition according to claim 1, wherein the alkaloid is present in the composition in basic form or in the form of a pharmaceutically acceptable salt. / P Aívw / 3. The analgesic preparation of claim 1, wherein the rosmarinic acid is present in the preparation in acid form or in the form of a salt with a pharmaceutically acceptable metal.